Pfizer has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla, regarding lawsuits filed in the US District Court for the District of Delaware for infringement of patents relating to VYNDAMAX (tafamidis), a treatment for cardiomyopathy transthyretin-mediated amyloidosis (ATTR-CM). These settlements extend the effective US patent expiry date for VYNDAMAX to June 1, 2031, subject to the outcome of other litigation.

Pfizer had previously anticipated a significant decline in US revenues for VYNDAMAX beginning in 2029 upon patent expiry. As a result of this settlement, revenues are now expected to remain relatively stable from 2028 through mid-2031.

Aamir Malik, Executive Vice President and Chief US Commercial Officer, Pfizer, said, "We are very pleased by this outcome, both for patients and in recognition of the value of our innovative science and the strength of our patents. Our focus continues to be our unwavering commitment to patients with ATTR-CM. With our market leadership and physician experience, we remain confident in the value and benefits of VYNDAMAX as we work to reach more patients living with this serious and underdiagnosed disease."

VYNDAMAX remains the market leader with 75 percent of prescription volume within the overall ATTR-CM market. As the only once-daily capsule approved for ATTR-CM with statistically significant reductions in both all-cause mortality and cardiovascular-related hospitalisations with a demonstrated safety profile comparable to placebo, VYNDAMAX is backed by over seven years of market leadership and data from more than 7,000 patients across clinical trials and the largest ATTR-CM registry to date.

As of December 31, 2025, Pfizer discontinued the supply of VYNDAQEL in the US with VYNDAMAX remaining available for eligible patients. The decision followed consultation with clinical experts and patient advocates who agreed that a single-capsule taken once daily enhances patient-centered care and convenience, particularly for those with concomitant conditions requiring multiple oral medications.